From October 1, 2023 to December 31, 2023, the company has repurchased 5,332,769 shares, representing 3.93% for $34.65 million. With this, the company has completed the repurchase of 6,613,780 shares, representing 4.87% for $44.05 million under the buyback announced on May 19, 2023.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.3 USD | -2.21% |
|
-5.53% | -41.89% |
12/06 | Cytek Biosciences to Seek M&A | CI |
12/06 | Transcript : Cytek Biosciences, Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-12-2024 09:20 AM |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-41.89% | 70Cr | |
+5.16% | 21TCr | |
+9.62% | 19TCr | |
+31.18% | 16TCr | |
+33.37% | 11TCr | |
+3.84% | 6.49TCr | |
+20.08% | 5.52TCr | |
+1.51% | 4.91TCr | |
-4.27% | 3.88TCr | |
+0.88% | 3.56TCr |
- Stock Market
- Equities
- CTKB Stock
- News Cytek Biosciences, Inc.
- Tranche Update on Cytek Biosciences, Inc.'s Equity Buyback Plan announced on May 19, 2023.